Photo Gallery

Login

Search

News & Updation

  • WJPPS SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2018 Issue has been successfully launched on 1 September 2018

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

FORMULATION DEVELOPMENT AND EVALUATION OF TRANSDERMAL PATCH OF ONDENSETRON HYDROCHLORIDE

*Arjun Uttam Bhamare, Dr. Avish D. Maru, Rajendra K. Surawase, Yashpal M. Moren, Snehal S. Magar, Digambar A. Nagare and Tushar N. Deore

ABSTRACT

The purpose of this research was to develop a matrix-type Transdermal therapeutic system containing drug Ondansetron hydrochloride with different ratio of hydrophilic and hydrophobic polymeric systems by using the film casting techniques on glass petridish of polyethylene glycol to the polymers such as Hydroxypropyl Methyl Cellulose incorporated as plasticizer and β-Cyclodextrine was used to enhance the Transdermal permeation of Ondensetron Hydrochloride. Formulated transdermal patches were physically evaluated with regard to thickness, moisture content, moisture uptake, tensile strength, folding endurance, flatness, drug content drug diffusion, and Surface Morphology. All of them F3 prepared formulations indicated good physical stability & better drug diffusion. The in vitro permeation studies of formulations were performed by using Franz diffusion cells. It was observed that the formulation F3 shows better extended release up to 8 hrs. The release rate found to follow first order rate kinetic. It’s having majority of importance in Chemotherapy-induced nausea and vomiting is a common side effect by cancer patients during chemotherapy treatment. Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist used in Chemotherapy-induced nausea and vomiting management. Orally administered Ondensetron Hydrochloride undergoes extensive hepatic first-pass metabolism, which accounts for its low bioavailability and short half-life. It tends to be vomited before being absorbed and has limited use in patients with difficulty swallowing after chemotherapy. In this situation Transdermal delivery is a potential route for the administration of Ondansetron hydrochloride.

Keywords: Ondensetron Hydrochloride, Penetration Enhancer. Sustained Released, Transdermal Patches.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More